About Phosphatidylinositol N-acetylglucosaminyltransferase subunit H
Phosphatidylinositol N-acetylglucosaminyltransferase subunit H (PIGH) is a protein
from Homo sapiens identified by UniProt accession
Q14442, 188 residues long.
MolForge cross-references it against 0 known binders and
35 disease associations.
Target properties
| Protein name | Phosphatidylinositol N-acetylglucosaminyltransferase subunit H |
|---|
| UniProt accession | Q14442 |
|---|
| Gene | PIGH |
|---|
| Organism | Homo sapiens |
|---|
| Length | 188 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (35)
Diseases linked to this target (Open Targets).
- glycosylphosphatidylinositol biosynthesis defect 17 · score 0.71
- epilepsy · score 0.37
- Febrile seizure (within the age range of 3 months to 6 years) · score 0.37
- neurodegenerative disease · score 0.30
- genetic disorder · score 0.19
- protein measurement · score 0.17
- prostate carcinoma · score 0.11
- prostate cancer · score 0.11
- Familial prostate cancer · score 0.11
- acute lymphoblastic leukemia · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q14442-F1 | alphafold | PREDICTED | 86.86 | — |
Amino-acid sequence (188 residues)
MEDERSFSDI CGGRLALQRR YYSPSCREFC LSCPRLSLRS LTAVTCTVWL AAYGLFTLCE NSMILSAAIF ITLLGLLGYL HFVKIDQETL LIIDSLGIQM TSSYASGKES TTFIEMGKVK DIVINEAIYM QKVIYYLCIL LKDPVEPHGI SQVVPVFQSA KPRLDCLIEV YRSCQEILAH QKATSTSP
Explore Phosphatidylinositol N-acetylglucosaminyltransferase subunit H with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets